NCT03521570View on ClinicalTrials.gov

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 28, 2018

Primary Completion Date

July 25, 2022

Study Completion Date

September 7, 2023

Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
RADIATION

IMRT

Undergo intensity-modulated radiation therapy

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (4)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

44195

Cleveland Clinic Foundation, Cleveland

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

The Cleveland Clinic

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER